Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-02-26

Clinical Trial Update: Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

Phase 3 randomized trial of rivoglitazone in type 2 diabetes mellitus was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rivoglitazone (rivoglitazone)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: TERMINATED | Results posted: 2021-02-26